Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Robin Harper Cowie net worth and biography

Robin Cowie Biography and Net Worth

CFO of Biodesix

Robin Harper Cowie has served as our Chief Financial Officer since April 2017. She has been with the Company in multiple financial and reimbursement positions since March 2011, serving as Vice President of Finance from February 2016 to April 2017, Vice President of Reimbursement & Health Economics from February 2015 to February 2016, Senior Director of Reimbursement from January 2014 to February 2015, and Director of Reimbursement from March 2011 to January 2014. Prior to joining Biodesix, Ms. Harper Cowie held a leadership role in payer and government relations at Precision Therapeutics, Inc. Ms. Harper Cowie’s background includes corporate finance, managed care and payer relations, reimbursement and regulatory policy, and revenue cycle operations. Additionally, she spent several years as a researcher at the University of Pittsburgh Medical Center. Ms. Harper Cowie holds a B.S. in Molecular Biology from the University of Pittsburgh, and an M.B.A. in Finance from the Joseph M. Katz Graduate School of Business from the University of Pittsburgh.

What is Robin Harper Cowie's net worth?: The estimated net worth of Robin Harper Cowie is at least $227,469.69 as of August 12th, 2024. Ms. Cowie owns 191,151 shares of Biodesix stock worth more than $227,470 as of November 20th. This net worth evaluation does not reflect any other assets that Ms. Cowie may own. Additionally, Ms. Cowie receives an annual salary of $390,300.00 as CFO at Biodesix. Learn More about Robin Harper Cowie's net worth.
How old is Robin Harper Cowie?: Ms. Cowie is currently 44 years old. There are 3 older executives and no younger executives at Biodesix. The oldest executive at Biodesix is Dr. Gary Anthony Pestano Ph.D., Chief Development Officer, who is 57 years old. Learn More on Robin Harper Cowie's age.
What is Robin Harper Cowie's salary?: As the CFO of Biodesix, Inc., Ms. Cowie earns $390,300.00 per year. There are 2 executives that earn more than Ms. Cowie. The highest earning executive at Biodesix is Mr. Scott Hutton, President, CEO & Director, who commands a salary of $614,920.00 per year. Learn More on Robin Harper Cowie's salary.
How do I contact Robin Harper Cowie?: The corporate mailing address for Ms. Cowie and other Biodesix executives is , , . Biodesix can also be reached via phone at 303-417-0500 and via email at [email protected]. Learn More on Robin Harper Cowie's contact information.
Has Robin Harper Cowie been buying or selling shares of Biodesix?: Robin Harper Cowie has not been actively trading shares of Biodesix during the past quarter. Most recently, Robin Harper Cowie sold 251 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $1.57, for a transaction totalling $394.07. Following the completion of the sale, the chief financial officer now directly owns 191,151 shares of the company's stock, valued at $300,107.07. Learn More on Robin Harper Cowie's trading history.
Who are Biodesix's active insiders?: Biodesix's insider roster includes Robin Cowie (CFO), Scott Hutton (CEO), John Patience (Chairman), Jack Schuler (Director), and Charles Watts (Director). Learn More on Biodesix's active insiders.
Are insiders buying or selling shares of Biodesix?: During the last twelve months, Biodesix insiders bought shares 2 times. They purchased a total of 115,000 shares worth more than $159,500.00. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 106,909 shares worth more than $189,592.09. The most recent insider tranaction occured on November, 5th when Director Matthew Strobeck bought 40,000 shares worth more than $56,000.00. Insiders at Biodesix own 69.2% of the company. Learn More about insider trades at Biodesix.
Information on this page was last updated on 11/5/2024.

Robin Harper Cowie Insider Trading History at Biodesix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/12/2024	Sell	251	$1.57	$394.07	191,151
8/9/2024	Sell	724	$1.60	$1,158.40	191,402
5/9/2024	Sell	980	$1.48	$1,450.40	171,680
2/12/2024	Sell	8,699	$1.66	$14,440.34	169,410
2/9/2024	Sell	10,156	$1.92	$19,499.52	178,109
11/9/2023	Sell	491	$1.27	$623.57	137,064
8/9/2023	Sell	1,789	$1.39	$2,486.71	133,323
5/9/2023	Sell	2,512	$1.57	$3,943.84	118,338
2/9/2023	Sell	4,220	$1.80	$7,596.00	99,275
11/9/2022	Sell	1,999	$1.04	$2,078.96	76,112
8/9/2022	Sell	3,533	$2.53	$8,938.49	66,537
5/10/2022	Sell	3,338	$1.83	$6,108.54	58,495
11/17/2021	Buy	1,000	$6.51	$6,510.00

Robin Harper Cowie Buying and Selling Activity at Biodesix

Biodesix Company Overview

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Today's Range

Now: $1.19

$1.11

$1.27

50 Day Range

MA: $1.59

$1.19

$1.80

2 Week Range

Now: $1.19

$1.11

$2.21

Volume

1,715,288 shs

Average Volume

181,083 shs

Market Capitalization

$173.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

This company will win the AI race

From Porter & Company | Ad

You must read this new presentation from Porter Stansberry.

Robin Cowie Biography and Net Worth

What is Robin Harper Cowie's net worth?

How old is Robin Harper Cowie?

What is Robin Harper Cowie's salary?

How do I contact Robin Harper Cowie?

Has Robin Harper Cowie been buying or selling shares of Biodesix?

Who are Biodesix's active insiders?

Are insiders buying or selling shares of Biodesix?